CTOs on the Move


 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Eyecarrot

Eyecarrot’s goal is to power a global, data-driven, expert therapeutic network to transform how human Oculomotor Sensory performance is diagnosed, exercised and enhanced. The company is building Binovi, a universal, collaborative care platform that integrates software, hardware, data and the expert knowledge and insights of vision care professionals to help patients on a global scale.

Cerebrio

Cerebrio is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accordant Health Services

Accordant helps members manage their rare or complex conditions.

Caris Diagnostics

Caris Diagnostics is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

America's PPO

America's PPO is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.